AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Morbilliform Reactions in Patients of Color

Description

The presentation discusses morbilliform reactions in patients of color, emphasizing the importance of recognizing these reactions, which can be subtle and easily misdiagnosed. The speaker highlights that a significant portion of the U.S. population will have darker skin tones by 2050, yet there is insufficient medical training on skin conditions affecting these groups, leading to delayed diagnoses and higher mortality rates. Erythema, a key feature of morbilliform eruptions, presents differently in patients of color, often appearing less pronounced and possibly dusky or purplish, making it harder to identify. Techniques such as improved lighting, palpation, and dermoscopy are recommended to aid in recognizing these conditions. Risk factors for severe adverse drug reactions in patients of color were discussed, including genetic predispositions and prescribing biases. Recent studies indicate that patients of color experience more severe manifestations of drug eruptions and face delays in drug withdrawal following onset of symptoms, which is concerning for health outcomes. Notably, higher mortality rates have been reported in black patients experiencing conditions like DRESS. The presentation underscores the need for awareness and tailored approaches to treating skin conditions in patients of color, particularly in the context of emerging immunotherapies.

View more

Conclusions

  • Skin of color will comprise over half the US population by 2050, highlighting the need for improved recognition of morbilliform reactions in this demographic.
  • Recognition of erythema in patients of color is challenging due to subtle manifestations; specific techniques can aid in diagnosis.
  • Patients of color experience delays in diagnosis and treatment, which correlate with increased mortality rates, particularly among black patients.
  • Certain genetic predispositions for drug reactions are more prevalent in patients of color, leading to higher risks of severe adverse drug eruptions.
  • Clinical differences exist in the presentation of drug reactions, with variations in symptoms such as erythema, pustules, and edema observed among different racial groups.
  • Increased mortality rates for black patients with DRESS syndrome compared to white patients reflect significant health disparities.
  • The potential for delayed drug withdrawal in patients of color following adverse reactions poses a serious concern for patient management.
  • Emerging immunotherapies can also lead to cutaneous eruptions in patients of color, necessitating heightened awareness among clinicians.
  • Journal of the American Academy of Dermatology (JAAD). Shaughnessy, Kerry K.; Bouchard, Susan M.; Mohr, Mel ... Vol. 62 Issue 2, pp. 315-318, 2010.
  • Bensken WP, Fernandez Baca Vaca G, Alberti PM, Khan OI, Ciesielski TH, Jobst BC, Williams SM, Stange KC, Sajatovic M, Koroukian SM. Racial and Ethnic Differences in Antiseizure Medications Among People With Epilepsy on Medicaid: A Case of Potential Inequities. Neurol Clin Pract. 2023 Feb;13(1)
  • Bean EL, Lewis DJ, Weir MA, Micheletti RG. Delayed diagnosis of DRESS syndrome in a patient with skin of color. Dermatol Online J. 2023 Feb 15;29(1).
  • Bassir F, Alvarez-Arango S, Kroshinsky D, Phillips E, Ezeofor AJ, Samarakoon U, Blackley SV, Wang L, Zhou L. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinical presentation and outcomes in people of color. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3537-3540.
  • Korman AM, Schneider JG, Gallardo M, Fisher K, Kaffenberger BH. Increased mortality among African American patients with DRESS syndrome compared to White patients. Int J Dermatol. 2024.
  • Wasuwanich P, So JM, Chakrala TS, Chen J, Motaparthi K. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. JAAD Int. 2023 Jul 11;13:17-25.